APA (7th ed.) Citation

Reza Safaei Nodehi, Behjat Kalantari, Jahangir Raafat, Nafiseh Ansarinejad, Vahid Moazed, Seyed Mohammad Reza Mortazavizadeh, . . . Farhad Shahi. (2022). A randomized, double-blind, phase III, non-inferiority clinical trial comparing the efficacy and safety of TA4415V (a proposed Trastuzumab biosimilar) and Herceptin (Trastuzumab reference product) in HER2-positive early-stage breast Cancer patients. BMC.

Chicago Style (17th ed.) Citation

Reza Safaei Nodehi, et al. A Randomized, Double-blind, Phase III, Non-inferiority Clinical Trial Comparing the Efficacy and Safety of TA4415V (a Proposed Trastuzumab Biosimilar) and Herceptin (Trastuzumab Reference Product) in HER2-positive Early-stage Breast Cancer Patients. BMC, 2022.

MLA (9th ed.) Citation

Reza Safaei Nodehi, et al. A Randomized, Double-blind, Phase III, Non-inferiority Clinical Trial Comparing the Efficacy and Safety of TA4415V (a Proposed Trastuzumab Biosimilar) and Herceptin (Trastuzumab Reference Product) in HER2-positive Early-stage Breast Cancer Patients. BMC, 2022.